Furthermore, a systematic review and meta-analysis of seven trials comparing short- and long-term outcomes of metformin versus insulin treatment in GDM reported a relative risk of 1.2 for SGA infants, although this did not reach statistical significance (95% CI, 0.85 to 1.04) [24]. This evidence concerns the gene INS and gestational diabetes.